Cryptosporidiosis: A Potential Anti-diarrheal Natural Product Drug Discovery Journey in Ghana, West Africa|Journal of Scientific Research and Reports

The increasing resistance to current medications, as well as the exhaustion of drug development interventions and synthetic libraries, has forced researchers to turn to natural product-derived innovative therapeutic prospects. Cryptosporidium, the organism that causes Cryptosporidiosis, is no different. The diarrhea-causing parasite is the primary cause of death in children under the age of five in underdeveloped countries such as Ghana, and is second only to rotavirus as the cause of diarrhoea in newborn calves and babies. Nitazoxanide is currently the sole FDA-approved medication for the treatment of Cryptosporidiosis. As a result, innovative alternative alternatives must be developed in order to help in the reduction of child mortality and malnutrition in poor nations. Despite major difficulties in the creation of anti-cryptosporidial drugs in vitro and in vivo, important progress is being made, and this paper highlights the need for natural product research. Some of the research included in this publication suggest that plant extracts may be effective against cryptosporidiosis. We are confident of achieving great achievements in the realm of natural product Cryptosporidium medication development in Africa with the plethora of medicinal plant products and Cryptosporidium in vitro culture knowledge accessible in our labs at Noguchi Memorial Institute for Medical Research.

Please click here : https://journaljsrr.com/index.php/JSRR/article/view/30311

Pharmacovigilance in Cameroon: Past, Present and Future Developments in Unlocking the Drug Development Process|Journal of Advances in Medical and Pharmaceutical Sciences

Drug development and discovery techniques are aimed to ensure that medications are effective, harmless, and of high quality for human consumption. However, the number of patients who have access to medications at the time of approval is a small percentage of the final target population. As a result, a complete understanding of the safety of medicines is usually only obtained after the drug has been approved for marketing, followed by pharmacovigilance or post-marketing surveillance. WHO defines pharmacovigilance (PHV) as “the science and activities concerned with the detection, assessment, understanding, and prevention of adverse drug responses or other potential drug-related interactions.” As a result, health professionals, patients, drug producers, and drug regulatory agencies are all heavily involved in PHV practise.
Cameroon imports 95% of its medications and medical supplies. As a result, a thorough understanding of PHV knowledge, attitude, and practise will aid in the development of our pharmacovigilance systems. This study provides an overview of pharmacovigilance in Cameroon, with an emphasis on the past, present, and future, in order to unlock the drug development process.

Please click here: https://journaljamps.com/index.php/JAMPS/article/view/30192  

Pharmacovigilance in Cameroon: Past, Present and Future Developments in Unlocking the Drug Development Process | Journal of Advances in Medical and Pharmaceutical Sciences

The drug discovery and development processes are designed to guarantee that drugs are efficacious, nontoxic and of high standards of quality for human consumption. However, patient’s population with access to drugs at approval is only a fraction of the final target population. Therefore, a thorough understanding of the safety of medicines is generally only achieved after the marketing authorization of the drug, followed by pharmacovigilance or post marketing surveillance. Pharmacovigilance (PHV) is defined by WHO as “the science and activities that deals with the detection, assessment, understanding and prevention of the adverse drug reactions or any other possible drug-related interactions”. Health professionals, patients, drug manufacturers and drug regulatory authorities are therefore highly involved in the practice of PHV. Cameroon imports 95 % of drugs and health care products. Therefore, an effective mastery of the knowledge, attitude and practice of PHV will help to elaborate the development of our pharmacovigilance systems. This paper gives an overview of pharmacovigilance in Cameroon for unlocking the drug development process focusing on the past, present and future.

Please see the link :- https://www.journaljamps.com/index.php/JAMPS/article/view/30192

Cryptosporidiosis: A Potential Anti-diarrheal Natural Product Drug Discovery Journey in Ghana, West Africa | West Africa. Journal of Scientific Research and Reports

The overwhelming resistance to existing medications, as well as the depletion of drug development interventions and synthetic libraries, has forced researchers to turn to natural product-derived novel drug  candidates.Cryptosporidium,  the organism that causes Cryptosporidiosis, is no different. The diarrheacausing parasite is the leading cause of death in children under the age of five in developing countries such as Ghana, and is second only to rotavirus as the causeof diarrhoea in newborn calvesand babies.Nitazoxanide is currently the only FDAapproved drug for the treatment of Cryptosporidiosis. As a result, novel alternative candidates must be developed in order to help in the reduction of infant mortality and malnutrition in developing countries. Despite major limitations in the production of anti-cryptosporidial drugs in vitro and in vivo,  important progress  is being made, and this article discusses the need for natural product research. Some of the studies cited in this paper suggest that plant extracts may be effective against cryptosporidiosis. We are confident of making major strides in the field of natural product Cryptosporidium drug development in Africa with the abundance of medicinal plant products and Cryptosporidium in vitro culture expertise available in our laboratories at Noguchi Memorial Institute for Medical Research.


Please see the link – https://www.journaljsrr.com/index.php/JSRR/article/view/30311